Mohammed Kanaan
Hematology & Oncology · Puyallup, WANPI 1326270992
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $484 of the $636 with a category attached, or 76.1%. 12 manufacturers reported payments, led by AbbVie at 26.8% of the total. 2025 is the largest year on record at $201, 3.9 times the $51 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in WA, where the typical reported total is $899.
Across 27 payments — averaging $23.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$171
- Tempus AI, Inc$131
- GSK$69
- E.r. Squibb & Sons, L.L.C.$58
- Sumitomo Pharma America, Inc.$43
- Incyte Corporation$43
- plus $121 from 6 others
Across 83 payments — averaging $6818.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$267K
- AVEO Pharmaceuticals, Inc.$159K
- Pfizer$137K
- Beigene, Ltd.$2K
What the payments were for
- Food & beverage$48476%
- Education$15224%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $171 |
| Tempus AI, Inc | 2 | $131 |
| GSK | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Incyte Corporation | 2 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $40 |
| Exelixis Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $21 |
| Coherus Oncology, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XT CDX$104
How this compares
$636 in reported general payments places this provider in the 45th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 45 | $938,022 |
| Lenalidomide | 21 | $286,292 |
| IbrancePalbociclib | 17 | $271,175 |
| CalquenceAcalabrutinib Maleate | 12 | $176,600 |
| Abiraterone Acetate | 88 | $155,644 |
| TasignaNilotinib Hcl | 12 | $109,432 |
| XareltoRivaroxaban | 25 | $34,167 |
| EliquisApixaban | 34 | $28,427 |
| Hydroxyurea | 52 | $1,366 |
| Oxycodone Hcl | 34 | $942 |
| Ondansetron OdtOndansetron | 15 | $473 |
| Prednisone | 80 | $404 |
| Gabapentin | 24 | $399 |
| Tamoxifen Citrate | 13 | $312 |
| Omeprazole | 32 | $214 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Puyallup
- Sibel BlauPuyallup$21K
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Thomas BoydSpokane$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.